KBFS
DFTX

Kohmann Bosshard Financial Services’s Definium Therapeutics DFTX Stock Holding History

Kohmann Bosshard Financial Services’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-66
Closed -$884 – 447
2025
Q4 		$884 Buy
+66
New +$817 ﹤0.01% 993
2025
Q1 		– Sell
-66
Closed -$459 – 587
2024
Q4 		$459 Buy
+66
New +$454 ﹤0.01% 649

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kohmann Bosshard Financial Services's DFTX Position: Q1 2026 in Review

Kohmann Bosshard Financial Services sold out of Definium Therapeutics (DFTX) in Q1 2026, closing a stake of 66 shares — an estimated $884 sold.

Kohmann Bosshard Financial Services first reported a position in DFTX in Q4 2024 and held it in 2 quarters. The position peaked at $884 in Q4 2025. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Kohmann Bosshard Financial Services reported no remaining Definium Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Kohmann Bosshard Financial Services sold 66 Definium Therapeutics shares in Q1 2026, an estimated $884.
  • Kohmann Bosshard Financial Services first reported a position in Definium Therapeutics in Q4 2024 and held it in 2 quarters.
  • Kohmann Bosshard Financial Services's Definium Therapeutics position peaked at $884 in Q4 2025.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Kohmann Bosshard Financial Services's 13F filing for Q1 2026, filed 23 Apr 2026.